Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

Accurate identification of patients likely to achieve long-progression-free survival (PFS) after chemoimmunotherapy is essential given the availability of less toxic alternatives, such as ibrutinib. Fludarabine, cyclophosphamide, and rituximab (FCR) achieved a high response rate, but continued relap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Thompson, Philip A., Tam, Constantine S., O’Brien, Susan M., Wierda, William G., Stingo, Francesco, Plunkett, William, Smith, Susan C., Kantarjian, Hagop M., Freireich, Emil J., Keating, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4760129/
https://ncbi.nlm.nih.gov/pubmed/26492934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-09-667675
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados